BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16838067)

  • 1. Peeling off the hidden genetic heterogeneities of cancers based on disease-relevant functional modules.
    Xu JZ; Guo Z; Zhang M; Li X; Li YJ; Rao SQ
    Mol Med; 2006; 12(1-3):25-33. PubMed ID: 16838067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering.
    Zhang W; Li L; Li X; Jiang W; Huo J; Wang Y; Lin M; Rao S
    BMC Genomics; 2007 Sep; 8():332. PubMed ID: 17888167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathway-based analysis of the hidden genetic heterogeneities in cancers.
    Zhao X; Zhong S; Zuo X; Lin M; Qin J; Luan Y; Zhang N; Liang Y; Rao S
    Genomics Proteomics Bioinformatics; 2014 Feb; 12(1):31-8. PubMed ID: 24462714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards precise classification of cancers based on robust gene functional expression profiles.
    Guo Z; Zhang T; Li X; Wang Q; Xu J; Yu H; Zhu J; Wang H; Wang C; Topol EJ; Wang Q; Rao S
    BMC Bioinformatics; 2005 Mar; 6():58. PubMed ID: 15774002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the hidden heterogeneities of breast cancer based on functional miRNA cluster.
    Li L; Liu C; Wang F; Miao W; Zhang J; Kang Z; Chen Y; Peng L
    PLoS One; 2014; 9(1):e87601. PubMed ID: 24498150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kernel Cox regression models for linking gene expression profiles to censored survival data.
    Li H; Luan Y
    Pac Symp Biocomput; 2003; ():65-76. PubMed ID: 12603018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of diffuse large B-cell lymphoma heterogeneity based on coupled two-way clustering].
    Li L; Li X; Chen YH; Guo Z; Jiang W; Zhagn RJ; Rao SQ
    Yi Chuan; 2006 Sep; 28(9):1129-34. PubMed ID: 16963424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data.
    Gui J; Li H
    Bioinformatics; 2005 Jul; 21(13):3001-8. PubMed ID: 15814556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
    Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
    J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.
    Veldman-Jones MH; Lai Z; Wappett M; Harbron CG; Barrett JC; Harrington EA; Thress KS
    Clin Cancer Res; 2015 May; 21(10):2367-78. PubMed ID: 25301847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kernel mixture survival models for identifying cancer subtypes, predicting patient's cancer types and survival probabilities.
    Ando T; Imoto S; Miyano S
    Genome Inform; 2004; 15(2):201-10. PubMed ID: 15706506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray-based classification of diffuse large B-cell lymphoma.
    Poulsen CB; Borup R; Nielsen FC; Borregaard N; Hansen M; Grønbaek K; Møller MB; Ralfkiaer E
    Eur J Haematol; 2005 Jun; 74(6):453-65. PubMed ID: 15876249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
    Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
    APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant?
    Sujobert P; Salles G; Bachy E
    Hematol Oncol Clin North Am; 2016 Dec; 30(6):1163-1177. PubMed ID: 27888873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited.
    Segal MR
    Biostatistics; 2006 Apr; 7(2):268-85. PubMed ID: 16284340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data.
    Kaderali L; Zander T; Faigle U; Wolf J; Schultze JL; Schrader R
    Bioinformatics; 2006 Jun; 22(12):1495-502. PubMed ID: 16554338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
    Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.